Cynthia DeLong
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Cholinesterase and Neurodegenerative Diseases, Dementia and Cognitive Impairment Research, Parkinson's Disease Mechanisms and Treatments
Most-Cited Works
- → Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model(2002)857 cited
- → Apolipoprotein E is essential for amyloid deposition in theAPPV717Ftransgenic mouse model of Alzheimer's disease(1999)485 cited
- → HumanAPOEIsoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice(2009)280 cited
- → Macrophage-Mediated Degradation of β-Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism(2009)66 cited
- → Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice(2012)42 cited
- → Statistical aspects of quantitative image analysis of β-amyloid in the APPV717F transgenic mouse model of Alzheimer's disease(2001)15 cited
- → O1‐10‐03: COMBINATION THERAPY WITH A PLAQUE‐SPECIFIC ABETA ANTIBODY AND BACE INHIBITOR RESULTS IN DRAMATIC PLAQUE LOWERING IN AGED PDAPP TRANSGENIC MICE(2014)7 cited
- → P3–231: Biochemical and histological studies of leucine rich repeat kinase 2 (LRRK2)(2006)
- → P1–003: Thiorphan infusion induces deposition of beta–amyloid in PDAPP transgenic mice(2006)
- → P3–444: Proteasomal inhibition increases alpha–synuclein levels in an amyloid–beta–dependent manner(2006)